New hope for kids with rare muscle disease: Long-Term drug safety trial begins
NCT ID NCT06435312
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety of a daily injection called zilucoplan in children with a rare muscle-weakening disease called generalized myasthenia gravis. It includes up to 8 children who have already completed a previous study. The goal is to see if the drug remains safe and tolerable over an additional 52 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mg0015 20104
Seoul, South Korea
-
Mg0015 20220
Seoul, South Korea
-
Mg0015 40144
Milan, Italy
-
Mg0015 40218
Warsaw, Poland
-
Mg0015 40735
Glasgow, United Kingdom
-
Mg0015 40736
London, United Kingdom
-
Mg0015 40774
Katowice, Poland